Opus Point Partners Management as of March 31, 2017
Portfolio Holdings for Opus Point Partners Management
Opus Point Partners Management holds 64 positions in its portfolio as reported in the March 2017 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| SPDR S&P Biotech (XBI) | 6.7 | $9.0M | 130k | 69.34 | |
| Bristol Myers Squibb (BMY) | 5.5 | $7.3M | 135k | 54.38 | |
| iShares NASDAQ Biotechnology Index (IBB) | 5.4 | $7.3M | 25k | 293.28 | |
| Alexion Pharmaceuticals | 4.8 | $6.5M | 54k | 121.22 | |
| Merck & Co (MRK) | 4.0 | $5.3M | 84k | 63.54 | |
| Alkermes (ALKS) | 3.7 | $4.9M | 84k | 58.50 | |
| Incyte Corporation (INCY) | 3.5 | $4.7M | 35k | 133.68 | |
| Alnylam Pharmaceuticals (ALNY) | 3.4 | $4.6M | 90k | 51.25 | |
| Nektar Therapeutics (NKTR) | 3.2 | $4.4M | 186k | 23.47 | |
| Seattle Genetics | 3.2 | $4.4M | 70k | 62.87 | |
| Proshares Tr pshs ult nasb (BIB) | 3.0 | $4.1M | 85k | 48.26 | |
| Pfizer (PFE) | 2.9 | $3.8M | 112k | 34.21 | |
| AstraZeneca (AZN) | 2.8 | $3.7M | 120k | 31.14 | |
| Vertex Pharmaceuticals Incorporated (VRTX) | 2.8 | $3.7M | 34k | 109.36 | |
| Celgene Corporation | 2.6 | $3.5M | 28k | 124.45 | |
| Mettler-Toledo International (MTD) | 2.5 | $3.4M | 7.2k | 478.85 | |
| Agios Pharmaceuticals (AGIO) | 2.5 | $3.4M | 57k | 58.40 | |
| Illumina (ILMN) | 2.5 | $3.3M | 19k | 170.65 | |
| Qiagen Nv | 2.4 | $3.2M | 112k | 28.97 | |
| Amgen (AMGN) | 2.4 | $3.2M | 19k | 164.06 | |
| Ionis Pharmaceuticals (IONS) | 2.4 | $3.2M | 79k | 40.20 | |
| Regeneron Pharmaceuticals (REGN) | 2.3 | $3.1M | 8.0k | 387.55 | |
| Biogen Idec (BIIB) | 2.3 | $3.1M | 11k | 273.41 | |
| BioMarin Pharmaceutical (BMRN) | 2.1 | $2.9M | 33k | 87.78 | |
| GlaxoSmithKline | 1.9 | $2.5M | 60k | 42.17 | |
| Pacira Pharmaceuticals (PCRX) | 1.7 | $2.3M | 50k | 45.60 | |
| Clovis Oncology | 1.4 | $1.9M | 30k | 63.67 | |
| Tesaro | 1.1 | $1.5M | 10k | 153.90 | |
| Paratek Pharmaceuticals | 1.1 | $1.5M | 80k | 19.25 | |
| Medicines Company | 1.0 | $1.4M | 28k | 48.89 | |
| Eli Lilly & Co. (LLY) | 0.9 | $1.3M | 15k | 84.13 | |
| Gilead Sciences (GILD) | 0.8 | $1.1M | 16k | 67.98 | |
| Adamas Pharmaceuticals | 0.8 | $1.1M | 60k | 17.50 | |
| Axsome Therapeutics (AXSM) | 0.8 | $1.0M | 267k | 3.90 | |
| Portola Pharmaceuticals | 0.7 | $980k | 25k | 39.20 | |
| New Senior Inv Grp | 0.6 | $854k | 84k | 10.20 | |
| Ultragenyx Pharmaceutical (RARE) | 0.6 | $827k | 12k | 67.78 | |
| Contrafect | 0.4 | $540k | 300k | 1.80 | |
| Heron Therapeutics (HRTX) | 0.3 | $476k | 32k | 14.99 | |
| Kite Pharma | 0.3 | $466k | 5.9k | 78.57 | |
| Recro Pharma (SCTL) | 0.3 | $441k | 51k | 8.74 | |
| Grifols S A Sponsored Adr R (GRFS) | 0.3 | $414k | 22k | 18.88 | |
| Direxion Shs Etf Tr sp biotch bl | 0.3 | $416k | 8.7k | 47.69 | |
| Charles River Laboratories (CRL) | 0.3 | $399k | 4.4k | 89.84 | |
| Neurocrine Biosciences (NBIX) | 0.3 | $398k | 9.2k | 43.34 | |
| Progenics Pharmaceuticals | 0.3 | $411k | 44k | 9.43 | |
| Quintiles Transnatio Hldgs I | 0.3 | $405k | 5.0k | 80.56 | |
| Juno Therapeutics | 0.3 | $400k | 18k | 22.19 | |
| Myriad Genetics (MYGN) | 0.3 | $393k | 21k | 19.19 | |
| Ligand Pharmaceuticals In (LGND) | 0.3 | $394k | 3.7k | 105.94 | |
| Akebia Therapeutics (AKBA) | 0.3 | $387k | 42k | 9.21 | |
| Lion Biotechnologies | 0.3 | $396k | 53k | 7.45 | |
| Bio-techne Corporation (TECH) | 0.3 | $385k | 3.8k | 101.58 | |
| United Therapeutics Corporation (UTHR) | 0.3 | $373k | 2.8k | 135.34 | |
| ACADIA Pharmaceuticals (ACAD) | 0.3 | $383k | 11k | 34.41 | |
| Intercept Pharmaceuticals In | 0.3 | $375k | 3.3k | 113.22 | |
| Alder Biopharmaceuticals | 0.3 | $371k | 18k | 20.78 | |
| Avexis | 0.3 | $380k | 5.0k | 76.00 | |
| Intrexon | 0.3 | $365k | 18k | 19.83 | |
| Scynexis | 0.3 | $368k | 133k | 2.76 | |
| Bioverativ Inc Com equity | 0.2 | $304k | 5.6k | 54.41 | |
| Axovant Sciences | 0.2 | $260k | 17k | 14.92 | |
| D Stemline Therapeutics | 0.1 | $176k | 21k | 8.55 | |
| Seres Therapeutics (MCRB) | 0.1 | $158k | 14k | 11.29 |
